MGRM Monogram Technologies Inc

Leading HIV Physician, Dr. Andrew Zolopa, to Discuss the Opportunity for Monogram's Trofile(TM) Assay SOUTH SAN FRANCISCO, Calif., April 26 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (NASDAQ:MGRM) announced that it will hold a conference call on Wednesday, May 2, 2007 at 4:30 p.m. (Eastern Time) to review the opportunity for its Trofile(TM) Assay in the light of the FDA Advisory Panel's recommendation that Pfizer's maraviroc be approved. Dr. Andrew Zolopa, Assistant Professor of Medicine at Stanford University, and a leading HIV specialist, will provide his analysis of how Monogram's Trofile Assay may be used in clinical practice with maraviroc. Monogram will also review its first quarter 2007 financial results. The call will be hosted by Mr. William D. Young, Chairman & CEO of Monogram. To participate in the live teleconference, please call (800) 565-5442 or (913) 312-1298 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available by following the appropriate links at http://www.monogrambio.com/ and clicking on the Investor Relations link. Following the live broadcast, a replay of the call will also be available at (888) 203-1112 or (719) 457-0820 for international callers, through Saturday, May 12, 2007. The replay passcode is 4138334 The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law. About Monogram Biosciences, Inc. Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com/. contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer Feinstein Kean Healthcare Tel: 650 624-4576 Tel: 415 677-2700 DATASOURCE: Monogram Biosciences, Inc. CONTACT: Alfred G. Merriweather, Chief Financial Officer of Monogram Biosciences, Inc., +1-650-624-4576, , or Jeremiah Hall, Feinstein Kean Healthcare, +1-415-677-2700, Web site: http://www.monogrambio.com/

Copyright